Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis
Abstract
:1. Introduction
2. Role of miRNAs 19b-3p in CAD
3. Role of miR-186-5p in CAD
4. Role of miR-331 and miR-151-3p in CAD
5. Role of miR-29a-3p in CAD
6. Role of miR-574-3p and miR-574-5p in CAD
7. Role of miR-1 in CAD
8. Role of miR-208 in CAD
9. Role of miR-223 in CAD
10. Role of miR-155 in CAD
11. Role of miR-423 in CAD
12. Role of miR-133b in CAD
13. Role of miR-30 in CAD
14. Role of microR-147b in CAD
15. Role of miR-638 in CAD
16. Conclusions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
CAD | Coronary artery disease |
CVD | Cardiovascular diseases |
MCI | Myocardial infarction |
AMI | Acute myocardial infarction |
CVDs | Cardiovascular disorders |
HDL | High-density lipoprotein |
ECs | Endothelial cells |
NFI-A | Nuclear factor I-A |
MCP-1 | Monocyte chemoattractant protein-1 |
FLT-1 | Fms-related receptor tyrosine kinase 1 |
HUVECs | Human umbilical vein endothelial cells |
VCAM-1 | Vascular cell adhesion molecule 1 |
OGT | O-GlcNAc transferase |
VR | Ventricular remodeling |
DCM- | Dilated cardiomyopathy |
hAVICs | Human calcific aortic valves |
VSMC | Vascular smooth muscle cell |
ECs | Endothelial cells |
RasGAP | Ras GTPase-activating protein |
HCM | Hypertrophic cardiomyopathy |
ROS | Reactive oxygen species |
MMPs | Matrix metalloproteinase |
IFN-γ | Interferon-γ |
TNF-α | Tumor necrosis factor |
VP | Vulnerable plaques |
STEMI | ST-segment-elevation myocardial infarction |
LOX | Lysyl oxidase |
DGCR8 | DiGeorge syndrome critical region 8 |
ICAM-1 | Intercellular adhesion molecule 1 |
eNOS | Endothelial nitric oxide synthase 3 |
MAPK | Mitogen-activated protein kinase |
C/EBP | CCAAT-enhancer-binding proteins α and β |
CHF- | Congestive heart failure |
References
- Khan, A.; Johnson, D.K.; Carlson, S.; Hocum-Stone, L.; Kelly, R.F.; Gravely, A.A.; Mbai, M.; Green, D.L.; Santilli, S.; Garcia, S.; et al. NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ10: A Randomized Double-Blind Trial. Ann. Vasc. Surg. 2020, 64, 292–302. [Google Scholar] [CrossRef] [PubMed]
- Naito, S.; Petersen, J.; Sequeira-Gross, T.; Zeller, T.; Reichenspurner, H.; Girdauskas, E. Circulating microRNAs vs. aortic diameter in bicuspid aortic valve aortopathy. Asian Cardiovasc. Thorac. Ann. 2020, 218492320927233. [Google Scholar] [CrossRef]
- Bhat, A.A.; Younes, S.N.; Raza, S.S.; Zarif, L.; Nisar, S.; Ahmed, I.; Mir, R.; Kumar, S.; Sharawat, S.K.; Hashem, S.; et al. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol. Cancer 2020, 19, 57. [Google Scholar] [CrossRef]
- Macfarlane, L.A.; Murphy, P.R. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genom. 2010, 11, 537–561. [Google Scholar] [CrossRef] [Green Version]
- Bartoszewski, R.; Sikorski, A.F. Editorial focus: Entering into the non-coding RNA era. Cell Mol. Biol. Lett. 2018, 23, 45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018, 9, 402. [Google Scholar] [CrossRef] [Green Version]
- Mir, R.; Jha, C.K.; Elfaki, I.; Javid, J.; Rehman, S.; Khullar, N.; Banu, S.; Chahal, S.M.S. Incidence of MicroR-4513C/T Gene Variability in Coronary Artery Disease—A Case-Control Study. Endocr. Metab. Immune Disord. Drug Targets 2019, 19, 1216–1223. [Google Scholar] [CrossRef]
- Elfaki, I.; Mir, R.; Mir, M.M.; AbuDuhier, F.M.; Babakr, A.T.; Barnawi, J. Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease. J. Pers. Med. 2019, 9, 51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elfaki, I.; Mir, R.; Abu-Duhier, F.M.; Jha, C.K.; Al-Alawy, A.I.; Babakr, A.T.; Habib, S.A.E. Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations with Type 2 Diabetes: A Case-Control Study. Curr. Drug Metab. 2020, 21, 1152–1160. [Google Scholar] [CrossRef]
- Elfaki, I.; Mir, R.; Almutairi, F.M.; Duhier, F.M.A. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac. J. Cancer Prev. 2018, 19, 2057–2070. [Google Scholar] [CrossRef]
- Jha, C.K.; Mir, R.; Elfaki, I.; Javid, J.; Babakr, A.T.; Banu, S.; Chahal, S.M.S. Evaluation of the Association of Omentin 1 rs2274907 A>T and rs2274908 G>A Gene Polymorphisms with Coronary Artery Disease in Indian Population: A Case Control Study. J. Pers. Med. 2019, 9, 30. [Google Scholar] [CrossRef] [Green Version]
- Mir, R.; Elfaki, I.; Jha, C.K.; Javid, J.; Rehman, S.; Banu, S.; Mir, M.M.; Babakr, A.T.; Chahal, S.M.S. Molecular Evaluation of MicroRNA-146 Gene Variability (rs2910164 C> G) and its Association with Increased Susceptibility to Coronary Artery Disease. Microrna 2020. [Google Scholar] [CrossRef] [PubMed]
- Elfaki, I.; Mir, R.; Abu-Duhier, F.M.; Khan, R.; Sakran, M. Phosphatidylinositol 3-kinase Glu545Lys and His1047Tyr Mutations are not Associated with T2D. Curr. Diabetes Rev. 2020, 16, 881–888. [Google Scholar] [CrossRef]
- Liu, X.; You, L.; Zhou, R.; Zhang, J. Significant association between functional microRNA polymorphisms and coronary heart disease susceptibility: A comprehensive meta-analysis involving 16484 subjects. Oncotarget 2017, 8, 5692–5702. [Google Scholar] [CrossRef] [Green Version]
- Jha, C.K.; Mir, R.; Elfaki, I.; Khullar, N.; Rehman, S.; Javid, J.; Banu, S.; Chahal, S.M.S. Potential Impact of MicroRNA-423 Gene Variability in Coronary Artery Disease. Endocr. Metab. Immune Disord. Drug Targets 2019, 19, 67–74. [Google Scholar] [CrossRef]
- Mir, R.; Jha, C.K.; Elfaki, I.; Rehman, S.; Javid, J.; Khullar, N.; Banu, S.; Chahal, S.M.S. MicroRNA-224 (rs188519172 A>G) Gene Variability is Associated with a Decreased Susceptibility to Coronary Artery Disease: A Case-Control Study. Microrna 2019, 8, 198–205. [Google Scholar] [CrossRef]
- Li, M.; Hu, X.; Zhu, J.; Zhu, C.; Zhu, S.; Liu, X.; Xu, J.; Han, S.; Yu, Z. Overexpression of miR-19b impairs cardiac development in zebrafish by targeting ctnnb1. Cell Physiol. Biochem. 2014, 33, 1988–2002. [Google Scholar] [CrossRef] [PubMed]
- Kanuri, S.H.; Ipe, J.; Kassab, K.; Gao, H.; Liu, Y.; Skaar, T.C.; Kreutz, R.P. Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction. Atherosclerosis 2018, 278, 232–239. [Google Scholar] [CrossRef] [PubMed]
- Song, D.W.; Ryu, J.Y.; Kim, J.O.; Kwon, E.J.; Kim, D.H. The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1. Biochem. J. 2014, 457, 151–162. [Google Scholar] [CrossRef]
- Navickas, R.; Gal, D.; Laucevicius, A.; Taparauskaite, A.; Zdanyte, M.; Holvoet, P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc. Res. 2016, 111, 322–337. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.; Ponnusamy, M.; Liu, C.; Gao, J.; Wang, K.; Li, P. MicroRNA as a Therapeutic Target in Cardiac Remodeling. BioMed Res. Int. 2017, 2017, 1278436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, Y.; Zhang, Y.C.; Chen, Y.; Xiang, Y.; Shen, C.X.; Li, Y.G. The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease. Sci. Rep. 2015, 5, 15132. [Google Scholar] [CrossRef]
- Liang, H.Z.; Li, S.F.; Zhang, F.; Wu, M.Y.; Li, C.L.; Song, J.X.; Lee, C.; Chen, H. Effect of Endothelial Microparticles Induced by Hypoxia on Migration and Angiogenesis of Human Umbilical Vein Endothelial Cells by Delivering MicroRNA-19b. Chin. Med. J. 2018, 131, 2726–2733. [Google Scholar] [CrossRef]
- Zeller, T.; Keller, T.; Ojeda, F.; Reichlin, T.; Twerenbold, R.; Tzikas, S.; Wild, P.S.; Reiter, M.; Czyz, E.; Lackner, K.J.; et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur. Heart J. 2014, 35, 2106–2114. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.J.; Zhao, X.; Liu, Y.Z.; Zeng, Q.T.; Mao, X.B.; Li, S.N.; Zhang, M.; Jiang, C.; Zhou, Y.; Qian, C.; et al. Circulating MiR-19b-3p, MiR-134-5p and MiR-186-5p are Promising Novel Biomarkers for Early Diagnosis of Acute Myocardial Infarction. Cell Physiol. Biochem. 2016, 38, 1015–1029. [Google Scholar] [CrossRef] [PubMed]
- Wang, F.; Long, G.; Zhao, C.; Li, H.; Chaugai, S.; Wang, Y.; Chen, C.; Wang, D.W. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J. Transl. Med. 2013, 11, 222. [Google Scholar] [CrossRef] [Green Version]
- Widera, C.; Gupta, S.K.; Lorenzen, J.M.; Bang, C.; Bauersachs, J.; Bethmann, K.; Kempf, T.; Wollert, K.C.; Thum, T. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J. Mol. Cell Cardiol. 2011, 51, 872–875. [Google Scholar] [CrossRef] [PubMed]
- Horvath, M.; Horvathova, V.; Hajek, P.; Stechovsky, C.; Honek, J.; Senolt, L.; Veselka, J. MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction. Sci. Rep. 2020, 10, 5845. [Google Scholar] [CrossRef] [Green Version]
- Hopkins, P.N. Molecular biology of atherosclerosis. Physiol. Rev. 2013, 93, 1317–1542. [Google Scholar] [CrossRef]
- Virani, S.S.; Alonso, A.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef]
- Razani, B.; Feng, C.; Coleman, T.; Emanuel, R.; Wen, H.; Hwang, S.; Ting, J.P.; Virgin, H.W.; Kastan, M.B.; Semenkovich, C.F. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 2012, 15, 534–544. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Yang, L.; Liang, X.; Zhu, G. MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1. Cell Physiol. Biochem. 2015, 36, 1371–1381. [Google Scholar] [CrossRef] [PubMed]
- Zhai, C.; Cheng, J.; Mujahid, H.; Wang, H.; Kong, J.; Yin, Y.; Li, J.; Zhang, Y.; Ji, X.; Chen, W. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. PLoS ONE 2014, 9, e90563. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.Y.; Song, G.L.; Zhai, X.Q.; Wang, L.; Liu, Q.L.; Zhou, M.S. MicroRNA-331 inhibits development of gastric cancer through targeting musashi1. World J. Gastrointest. Oncol. 2019, 11, 705–716. [Google Scholar] [CrossRef]
- Qin, D.N.; Qian, L.; Hu, D.L.; Yu, Z.B.; Han, S.P.; Zhu, C.; Wang, X.; Hu, X. Effects of miR-19b overexpression on proliferation, differentiation, apoptosis and Wnt/beta-catenin signaling pathway in P19 cell model of cardiac differentiation in vitro. Cell Biochem. Biophys. 2013, 66, 709–722. [Google Scholar] [CrossRef]
- Marfella, R.; Di Filippo, C.; Potenza, N.; Sardu, C.; Rizzo, M.R.; Siniscalchi, M.; Musacchio, E.; Barbieri, M.; Mauro, C.; Mosca, N.; et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: Responders vs. non-responders. Eur. J. Heart Fail. 2013, 15, 1277–1288. [Google Scholar] [CrossRef] [Green Version]
- Meder, B.; Keller, A.; Vogel, B.; Haas, J.; Sedaghat-Hamedani, F.; Kayvanpour, E.; Just, S.; Borries, A.; Rudloff, J.; Leidinger, P.; et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res. Cardiol. 2011, 106, 13–23. [Google Scholar] [CrossRef] [PubMed]
- Deng, X.; Chu, X.; Wang, P.; Ma, X.; Wei, C.; Sun, C.; Yang, J.; Li, Y. MicroRNA-29a-3p Reduces TNFalpha-Induced Endothelial Dysfunction by Targeting Tumor Necrosis Factor Receptor 1. Mol. Ther. Nucleic Acids 2019, 18, 903–915. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Yuan, Y.; Qiu, C. Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med. Sci. Monit. 2016, 22, 2175–2181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fang, L.; Ellims, A.H.; Moore, X.L.; White, D.A.; Taylor, A.J.; Chin-Dusting, J.; Dart, A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med. 2015, 13, 314. [Google Scholar] [CrossRef] [PubMed]
- Kriegel, A.J.; Liu, Y.; Fang, Y.; Ding, X.; Liang, M. The miR-29 family: Genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol. Genom. 2012, 44, 237–244. [Google Scholar] [CrossRef]
- Zhang, L.; Zhang, J.; Tong, Q.; Wang, G.; Dong, H.; Wang, Z.; Sun, Q.; Wu, H. Reduction of miR-29a-3p induced cardiac ischemia reperfusion injury in mice via targeting Bax. Exp. Ther. Med. 2019, 18, 1729–1737. [Google Scholar] [CrossRef] [PubMed]
- Yang, K.; Shen, Q.; Lei, S.; Lu, T.; Cai, X.; Guo, L.; Sun, G.; Lv, G.; Sun, X.; Chen, S. Identifying microRNA biomarkers and constructing microRNA-regulated networks in coronary artery diseases: A meta-analysis. Int. J. Clin. Exp. Med. 2019, 12, 2899–2911. [Google Scholar]
- Widlansky, M.E.; Jensen, D.M.; Wang, J.; Liu, Y.; Geurts, A.M.; Kriegel, A.J.; Liu, P.; Ying, R.; Zhang, G.; Casati, M.; et al. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol. Med. 2018, 10, e8046. [Google Scholar] [CrossRef] [Green Version]
- Li, M.; Wang, N.; Zhang, J.; He, H.P.; Gong, H.Q.; Zhang, R.; Song, T.F.; Zhang, L.N.; Guo, Z.X.; Cao, D.S.; et al. MicroRNA-29a-3p attenuates ET-1-induced hypertrophic responses in H9c2 cardiomyocytes. Gene 2016, 585, 44–50. [Google Scholar] [CrossRef]
- Zhang, L.; Zhang, Y.; Xue, S.; Ding, H.; Wang, Y.; Qi, H.; Wang, Y.; Zhu, W.; Li, P. Clinical significance of circulating microRNAs as diagnostic biomarkers for coronary artery disease. J. Cell Mol. Med. 2020, 24, 1146–1150. [Google Scholar] [CrossRef] [Green Version]
- Bostjancic, E.; Zidar, N.; Glavac, D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. BMC Genom. 2012, 13, 552. [Google Scholar] [CrossRef] [Green Version]
- Salinas, J.; Lin, H.; Aparico, H.J.; Huan, T.; Liu, C.; Rong, J.; Beiser, A.; Himali, J.J.; Freedman, J.E.; Larson, M.G.; et al. Whole blood microRNA expression associated with stroke: Results from the Framingham Heart Study. PLoS ONE 2019, 14, e0219261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, J.; Shao, G.; Chen, X.; Yang, X.; Huang, X.; Peng, P.; Ba, Y.; Zhang, L.; Jehangir, T.; Bu, S.; et al. miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. Biosci. Rep. 2015, 36, e00295. [Google Scholar] [CrossRef]
- Ku, T.; Li, B.; Gao, R.; Zhang, Y.; Yan, W.; Ji, X.; Li, G.; Sang, N. NF-kappaB-regulated microRNA-574-5p underlies synaptic and cognitive impairment in response to atmospheric PM2.5 aspiration. Part. Fibre Toxicol. 2017, 14, 34. [Google Scholar] [CrossRef] [Green Version]
- Lai, Z.; Lin, P.; Weng, X.; Su, J.; Chen, Y.; He, Y.; Wu, G.; Wang, J.; Yu, Y.; Zhang, L. MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease. Biomed. Pharmacother. 2018, 97, 162–167. [Google Scholar] [CrossRef] [PubMed]
- Li, K.; Wei, P.; Qin, Y.; Wei, Y. MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in obstructive sleep apnea patients. Medicine 2017, 96, e7917. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Dong, X.; Wang, Z.; Wu, J. MicroRNA-1 in Cardiac Diseases and Cancers. Korean J. Physiol. Pharmacol. 2014, 18, 359–363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tao, G.; Martin, J.F. MicroRNAs get to the heart of development. eLife 2013, 2, e01710. [Google Scholar] [CrossRef]
- Mishima, Y.; Stahlhut, C.; Giraldez, A.J. miR-1-2 gets to the heart of the matter. Cell 2007, 129, 247–249. [Google Scholar] [CrossRef] [Green Version]
- Heidersbach, A.; Saxby, C.; Carver-Moore, K.; Huang, Y.; Ang, Y.S.; de Jong, P.J.; Ivey, K.N.; Srivastava, D. microRNA-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart. eLife 2013, 2, e01323. [Google Scholar] [CrossRef]
- Zhao, Y.; Samal, E.; Srivastava, D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436, 214–220. [Google Scholar] [CrossRef] [PubMed]
- Girmatsion, Z.; Biliczki, P.; Bonauer, A.; Wimmer-Greinecker, G.; Scherer, M.; Moritz, A.; Bukowska, A.; Goette, A.; Nattel, S.; Hohnloser, S.H.; et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009, 6, 1802–1809. [Google Scholar] [CrossRef]
- Costantini, D.L.; Arruda, E.P.; Agarwal, P.; Kim, K.H.; Zhu, Y.; Zhu, W.; Lebel, M.; Cheng, C.W.; Park, C.Y.; Pierce, S.A.; et al. The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 2005, 123, 347–358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bostjancic, E.; Zidar, N.; Stajer, D.; Glavac, D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010, 115, 163–169. [Google Scholar] [CrossRef]
- Sayed, D.; Hong, C.; Chen, I.Y.; Lypowy, J.; Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 2007, 100, 416–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qipshidze Kelm, N.; Piell, K.M.; Wang, E.; Cole, M.P. MicroRNAs as predictive biomarkers for myocardial injury in aged mice following myocardial infarction. J. Cell Physiol. 2018, 233, 5214–5221. [Google Scholar] [CrossRef] [PubMed]
- Kura, B.; Kalocayova, B.; Devaux, Y.; Bartekova, M. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int. J. Mol. Sci. 2020, 21, 700. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Callis, T.E.; Pandya, K.; Seok, H.Y.; Tang, R.H.; Tatsuguchi, M.; Huang, Z.P.; Chen, J.F.; Deng, Z.; Gunn, B.; Shumate, J.; et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Investig. 2009, 119, 2772–2786. [Google Scholar] [CrossRef] [Green Version]
- Ji, X.; Takahashi, R.; Hiura, Y.; Hirokawa, G.; Fukushima, Y.; Iwai, N. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 2009, 55, 1944–1949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Montgomery, R.L.; Hullinger, T.G.; Semus, H.M.; Dickinson, B.A.; Seto, A.G.; Lynch, J.M.; Stack, C.; Latimer, P.A.; Olson, E.N.; van Rooij, E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124, 1537–1547. [Google Scholar] [CrossRef] [Green Version]
- Huang, Y.; Li, J. MicroRNA208 family in cardiovascular diseases: Therapeutic implication and potential biomarker. J. Physiol. Biochem. 2015, 71, 479–486. [Google Scholar] [CrossRef]
- Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303, 83–86. [Google Scholar] [CrossRef] [Green Version]
- Laffont, B.; Corduan, A.; Ple, H.; Duchez, A.C.; Cloutier, N.; Boilard, E.; Provost, P. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013, 122, 253–261. [Google Scholar] [CrossRef] [Green Version]
- Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13, 423–433. [Google Scholar] [CrossRef] [Green Version]
- Tabet, F.; Vickers, K.C.; Cuesta Torres, L.F.; Wiese, C.B.; Shoucri, B.M.; Lambert, G.; Catherinet, C.; Prado-Lourenco, L.; Levin, M.G.; Thacker, S.; et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 2014, 5, 3292. [Google Scholar] [CrossRef] [Green Version]
- Li, S.; Zhu, J.; Zhang, W.; Chen, Y.; Zhang, K.; Popescu, L.M.; Ma, X.; Lau, W.B.; Rong, R.; Yu, X.; et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011, 124, 175–184. [Google Scholar] [CrossRef] [Green Version]
- Pueyo, M.E.; Gonzalez, W.; Nicoletti, A.; Savoie, F.; Arnal, J.F.; Michel, J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arter. Thromb. Vasc. Biol. 2000, 20, 645–651. [Google Scholar] [CrossRef] [Green Version]
- Ye, Z.L.; Lu, H.L.; Su, Q.; Li, L. Association between the level of CD4(+) T lymphocyte microRNA-155 and coronary artery disease in patients with unstable angina pectoris. J. Geriatr. Cardiol. 2018, 15, 611–617. [Google Scholar] [CrossRef] [PubMed]
- Zhu, N.; Zhang, D.; Chen, S.; Liu, X.; Lin, L.; Huang, X.; Guo, Z.; Liu, J.; Wang, Y.; Yuan, W.; et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 2011, 215, 286–293. [Google Scholar] [CrossRef] [PubMed]
- Zhan, Y.; Brown, C.; Maynard, E.; Anshelevich, A.; Ni, W.; Ho, I.C.; Oettgen, P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J. Clin. Investig. 2005, 115, 2508–2516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, W.; Liu, T.; Jiang, F.; Liu, C.; Zhao, X.; Gao, Y.; Wang, H.; Liu, Z. microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int. J. Mol. Med. 2011, 27, 393–399. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.X.; Zeng, D.Y.; Li, R.T.; Pang, R.P.; Yang, H.; Hu, Y.L.; Zhang, Q.; Jiang, Y.; Huang, L.Y.; Tang, Y.B.; et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012, 60, 1407–1414. [Google Scholar] [CrossRef] [Green Version]
- Wu, X.Y.; Fan, W.D.; Fang, R.; Wu, G.F. Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-kappaB P65. J. Cell Biochem. 2014, 115, 1928–1936. [Google Scholar] [CrossRef]
- Fichtlscherer, S.; De Rosa, S.; Fox, H.; Schwietz, T.; Fischer, A.; Liebetrau, C.; Weber, M.; Hamm, C.W.; Roxe, T.; Muller-Ardogan, M.; et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010, 107, 677–684. [Google Scholar] [CrossRef] [Green Version]
- Evangelista, I.; Nuti, R.; Picchioni, T.; Dotta, F.; Palazzuoli, A. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. Int. J. Mol. Sci. 2019, 20, 3264. [Google Scholar] [CrossRef] [Green Version]
- Guo, Q.; Zhang, H.; Zhang, B.; Zhang, E.; Wu, Y. Tumor Necrosis Factor-alpha (TNF-alpha) Enhances miR-155-Mediated Endothelial Senescence by Targeting Sirtuin1 (SIRT1). Med. Sci. Monit. 2019, 25, 8820–8835. [Google Scholar] [CrossRef]
- Faccini, J.; Ruidavets, J.B.; Cordelier, P.; Martins, F.; Maoret, J.J.; Bongard, V.; Ferrieres, J.; Roncalli, J.; Elbaz, M.; Vindis, C. Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Sci. Rep. 2017, 7, 42916. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyamoto, S.; Usami, S.; Kuwabara, Y.; Horie, T.; Baba, O.; Hakuno, D.; Nakashima, Y.; Nishiga, M.; Izuhara, M.; Nakao, T.; et al. Expression Patterns of miRNA-423-5p in the Serum and Pericardial Fluid in Patients Undergoing Cardiac Surgery. PLoS ONE 2015, 10, e0142904. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Dong, Y.; Fang, T.; Wang, X.; Chen, L.; Zheng, C.; Kang, Y.; Jiang, L.; You, X.; Gai, S.; et al. Circulating MicroRNA-423-3p Improves the Prediction of Coronary Artery Disease in a General Population- Six-Year Follow-up Results from the China-Cardiovascular Disease Study. Circ. J. 2020, 84, 1155–1162. [Google Scholar] [CrossRef]
- Goldraich, L.A.; Martinelli, N.C.; Matte, U.; Cohen, C.; Andrades, M.; Pimentel, M.; Biolo, A.; Clausell, N.; Rohde, L.E. Transcoronary gradient of plasma microRNA 423-5p in heart failure: Evidence of altered myocardial expression. Biomarkers 2014, 19, 135–141. [Google Scholar] [CrossRef]
- Goren, Y.; Kushnir, M.; Zafrir, B.; Tabak, S.; Lewis, B.S.; Amir, O. Serum levels of microRNAs in patients with heart failure. Eur. J. Heart Fail. 2012, 14, 147–154. [Google Scholar] [CrossRef]
- Tijsen, A.J.; Creemers, E.E.; Moerland, P.D.; de Windt, L.J.; van der Wal, A.C.; Kok, W.E.; Pinto, Y.M. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 2010, 106, 1035–1039. [Google Scholar] [CrossRef]
- Romaine, S.P.; Tomaszewski, M.; Condorelli, G.; Samani, N.J. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart 2015, 101, 921–928. [Google Scholar] [CrossRef] [PubMed]
- Yan, H.; Ma, F.; Zhang, Y.; Wang, C.; Qiu, D.; Zhou, K.; Hua, Y.; Li, Y. miRNAs as biomarkers for diagnosis of heart failure: A systematic review and meta-analysis. Medicine 2017, 96, e6825. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Gao, J.; Wang, F. MiR-663a/MiR-423-5p are involved in the pathogenesis of lupus nephritis via modulating the activation of NF-kappaB by targeting TNIP2. Am. J. Transl. Res. 2017, 9, 3796–3803. [Google Scholar]
- Jouni, H.; Rodeheffer, R.J.; Kullo, I.J. Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries. Arter. Thromb. Vasc. Biol. 2011, 31, 197–202. [Google Scholar] [CrossRef] [Green Version]
- Jantti, T.; Segersvard, H.; Tolppanen, H.; Tarvasmaki, T.; Lassus, J.; Devaux, Y.; Vausort, M.; Pulkki, K.; Sionis, A.; Bayes-Genis, A.; et al. Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock. ESC Heart Fail. 2019, 6, 98–102. [Google Scholar] [CrossRef]
- Nabialek, E.; Wanha, W.; Kula, D.; Jadczyk, T.; Krajewska, M.; Kowalowka, A.; Dworowy, S.; Hrycek, E.; Wludarczyk, W.; Parma, Z.; et al. Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol. 2013, 61, 627–637. [Google Scholar]
- Rizzacasa, B.; Morini, E.; Mango, R.; Vancheri, C.; Budassi, S.; Massaro, G.; Maletta, S.; Macrini, M.; D’Annibale, S.; Romeo, F.; et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study. PLoS ONE 2019, 14, e0216363. [Google Scholar] [CrossRef] [Green Version]
- Zhou, S.S.; Jin, J.P.; Wang, J.Q.; Zhang, Z.G.; Freedman, J.H.; Zheng, Y.; Cai, L. miRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges. Acta Pharmacol. Sin. 2018, 39, 1073–1084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luo, P.; He, T.; Jiang, R.; Li, G. MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in cardiomyocytes. Mol. Med. Rep. 2015, 12, 1163–1168. [Google Scholar] [CrossRef] [PubMed]
- Barkovskaya, A.; Seip, K.; Hilmarsdottir, B.; Maelandsmo, G.M.; Moestue, S.A.; Itkonen, H.M. O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. Sci. Rep. 2019, 9, 5670. [Google Scholar] [CrossRef] [PubMed]
- Aubrey, B.J.; Kelly, G.L.; Janic, A.; Herold, M.J.; Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018, 25, 104–113. [Google Scholar] [CrossRef] [Green Version]
- Abdellatif, M. The role of microRNA-133 in cardiac hypertrophy uncovered. Circ. Res. 2010, 106, 16–18. [Google Scholar] [CrossRef]
- Care, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M.L.; Segnalini, P.; Gu, Y.; Dalton, N.D.; et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13, 613–618. [Google Scholar] [CrossRef]
- Gupta, S.K.; Bang, C.; Thum, T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3, 484–488. [Google Scholar] [CrossRef] [Green Version]
- Kuwabara, Y.; Ono, K.; Horie, T.; Nishi, H.; Nagao, K.; Kinoshita, M.; Watanabe, S.; Baba, O.; Kojima, Y.; Shizuta, S.; et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011, 4, 446–454. [Google Scholar] [CrossRef] [PubMed]
- Eitel, I.; Adams, V.; Dieterich, P.; Fuernau, G.; de Waha, S.; Desch, S.; Schuler, G.; Thiele, H. Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J. 2012, 164, 706–714. [Google Scholar] [CrossRef] [PubMed]
- Kumar, D.; Narang, R.; Sreenivas, V.; Rastogi, V.; Bhatia, J.; Saluja, D.; Srivastava, K. Circulatory miR-133b and miR-21 as Novel Biomarkers in Early Prediction and Diagnosis of Coronary Artery Disease. Genes 2020, 11, 164. [Google Scholar] [CrossRef] [Green Version]
- Mao, L.; Liu, S.; Hu, L.; Jia, L.; Wang, H.; Guo, M.; Chen, C.; Liu, Y.; Xu, L. miR-30 Family: A Promising Regulator in Development and Disease. BioMed Res. Int. 2018, 2018, 9623412. [Google Scholar] [CrossRef] [Green Version]
- Akodad, M.; Mericskay, M.; Roubille, F. Micro-RNAs as promising biomarkers in cardiac diseases. Ann. Transl. Med. 2016, 4, 551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, X.; Dong, S.; Jia, Q.; Zhang, A.; Li, Y.; Zhu, Y.; Lv, S.; Zhang, J. The microRNA in ventricular remodeling: The miR-30 family. Biosci. Rep. 2019. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Q.; Ma, X.F.; Dong, M.Z.; Tan, J.; Zhang, J.; Zhuang, L.K.; Liu, S.S.; Xin, Y.N. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line. Lipids Health Dis. 2020, 19, 76. [Google Scholar] [CrossRef] [Green Version]
- Fu, X.M.; Zhou, Y.Z.; Cheng, Z.; Liao, X.B.; Zhou, X.M. MicroRNAs: Novel Players in Aortic Aneurysm. BioMed Res. Int. 2015, 2015, 831641. [Google Scholar] [CrossRef] [Green Version]
- Zaragosi, L.E.; Wdziekonski, B.; Brigand, K.L.; Villageois, P.; Mari, B.; Waldmann, R.; Dani, C.; Barbry, P. Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011, 12, R64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, C.; Liu, J.; Yao, X.; Bai, Y.; Zhao, Q.; Zhao, R.; Kou, B.; Li, H.; Han, P.; Wang, X.; et al. Downregulation of microR-147b represses the proliferation and invasion of thyroid carcinoma cells by inhibiting Wnt/beta-catenin signaling via targeting SOX15. Mol. Cell Endocrinol. 2020, 501, 110662. [Google Scholar] [CrossRef]
- Chatterjee, V.; Beard, R.S., Jr.; Reynolds, J.J.; Haines, R.; Guo, M.; Rubin, M.; Guido, J.; Wu, M.H.; Yuan, S.Y. MicroRNA-147b regulates vascular endothelial barrier function by targeting ADAM15 expression. PLoS ONE 2014, 9, e110286. [Google Scholar] [CrossRef] [Green Version]
- Huang, Y.M.; Li, W.W.; Wu, J.; Han, M.; Li, B.H. The diagnostic value of circulating microRNAs in heart failure. Exp. Ther. Med. 2019, 17, 1985–2003. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gu, M.; Wang, J.; Wang, Y.; Xu, Y.; Zhang, Y.; Wu, W.; Liao, S. MiR-147b inhibits cell viability and promotes apoptosis of rat H9c2 cardiomyocytes via down-regulating KLF13 expression. Acta Biochim. Biophys. Sin. 2018, 50, 288–297. [Google Scholar] [CrossRef] [Green Version]
- Yao, Y.; Suo, A.L.; Li, Z.F.; Liu, L.Y.; Tian, T.; Ni, L.; Zhang, W.G.; Nan, K.J.; Song, T.S.; Huang, C. MicroRNA profiling of human gastric cancer. Mol. Med. Rep. 2009, 2, 963–970. [Google Scholar] [CrossRef] [Green Version]
- Luque, A.; Farwati, A.; Krupinski, J.; Aran, J.M. Association between low levels of serum miR-638 and atherosclerotic plaque vulnerability in patients with high-grade carotid stenosis. J. Neurosurg. 2018, 131, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Li, P.; Liu, Y.; Yi, B.; Wang, G.; You, X.; Zhao, X.; Summer, R.; Qin, Y.; Sun, J. MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1. Cardiovasc. Res. 2013, 99, 185–193. [Google Scholar] [CrossRef] [Green Version]
- Wong, L.L.; Armugam, A.; Sepramaniam, S.; Karolina, D.S.; Lim, K.Y.; Lim, J.Y.; Chong, J.P.; Ng, J.Y.; Chen, Y.T.; Chan, M.M.; et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur. J. Heart Fail. 2015, 17, 393–404. [Google Scholar] [CrossRef] [PubMed]
- Jiao, W.; Zhang, D.; Wang, D.; Xu, R.; Tang, L.; Zhao, M.; Xu, R. MicroRNA-638 inhibits human aortic valve interstitial cell calcification by targeting Sp7. J. Cell Mol. Med. 2019, 23, 5292–5302. [Google Scholar] [CrossRef] [Green Version]
microRNA | Target | Regulation Factors/Effects/Pathways | References |
---|---|---|---|
miR-19b-3p | PGC-1α, ABCA1,TF (procoagulant protein), Arigin I, MuRF I (muscle RING finger protein 1),TGFβRII | Accumulation of foam cells and macrophages, calcineurin/NFAT PKC/TGFβsignaling | [35] |
miR-134-5p | PI3K/Akt/mTOR, CREB A12B (HSPA12B) | Interferon-γ (IFN-γ), matrix metalloproteinase (MMPs), tumor necrosis factor (TNF-α) and cytokines | [36] |
miR-186-5p | PI3K/Akt/mTOR | Interferon-γ (IFN-γ), matrix metalloproteinase (MMPs), tumor necrosis factor (TNF-α) and cytokines | [37] |
miR-331 | SOCS1 | JAK and signal transducers gets inhibited STAT gets activated | [24] |
miR-151-3p | SOCS1 | JAK and signal transducers gets inhibited STAT gets activated | [25] |
miRNAs | Species | Diseases | Phenotype |
---|---|---|---|
miR-208a | Human | AM | Over-expressed |
Rat | Myocardial injury | Over-expressed | |
Human | AMI and AP | Over-expressed | |
Human | HF | Over-expressed | |
Rat | High-salt diet | Downregulated | |
Human | DCM | Over-expressed | |
H9C2 | Mechanical stretch | Downregulated | |
Rat | AV shunt | Over-expressed | |
Human | AMI | Over-expressed | |
miR-208b | Human | AMI | Over-expressed |
Human | AMI | Over-expressed | |
Human | Acute STEMI | Over-expressed | |
Human | Acute STEMI and NSTEMI | Over-expressed | |
Rat | High-salt diet | Over-expressed | |
Mouse | TAB | Over-expressed | |
miR-499 | Human | AMI and acute HF | Over-expressed |
Human | AMI | Over-expressed | |
Human | Acute STEMI and NSTEMI | Over-expressed | |
Human | AMI and AP | Over-expressed | |
Human | AF | Over-expressed | |
Human | HF | Over-expressed | |
Human | Acute NSTEMI | Over-expressed |
miRNA ID | Change in Expression | Purpose | Pathology |
---|---|---|---|
miR-30a | Increased | Diagnostic | MI |
miR-30b | Decreased | Diagnostic | AHF |
miR-30c | Decreased | Diagnostic | AMI |
Decreased | Diagnostic | Fibrosis | |
miR-30d | Decreased | Diagnostic and prognostic | CHF |
miR147 | Decreased | Diagnostic | AP |
miR-638 | Decreased | Diagnostic and prognostic | CS |
Increased | Diagnostic | hAVICs |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mir, R.; Elfaki, I.; Khullar, N.; Waza, A.A.; Jha, C.; Mir, M.M.; Nisa, S.; Mohammad, B.; Mir, T.A.; Maqbool, M.; et al. Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis. J. Cardiovasc. Dev. Dis. 2021, 8, 22. https://doi.org/10.3390/jcdd8020022
Mir R, Elfaki I, Khullar N, Waza AA, Jha C, Mir MM, Nisa S, Mohammad B, Mir TA, Maqbool M, et al. Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis. Journal of Cardiovascular Development and Disease. 2021; 8(2):22. https://doi.org/10.3390/jcdd8020022
Chicago/Turabian StyleMir, Rashid, Imadeldin Elfaki, Naina Khullar, Ajaz Ahmad Waza, Chandan Jha, Mohammad Muzaffar Mir, Shamsu Nisa, Babar Mohammad, Tahir Ahmad Mir, Mohsin Maqbool, and et al. 2021. "Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis" Journal of Cardiovascular Development and Disease 8, no. 2: 22. https://doi.org/10.3390/jcdd8020022
APA StyleMir, R., Elfaki, I., Khullar, N., Waza, A. A., Jha, C., Mir, M. M., Nisa, S., Mohammad, B., Mir, T. A., Maqbool, M., Barnawi, J., Albalawi, S. O., & Abu-Duhier, F. M. (2021). Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis. Journal of Cardiovascular Development and Disease, 8(2), 22. https://doi.org/10.3390/jcdd8020022